Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma

摘要

Copyright © 2017 by the Congress of Neurological SurgeonsStandard treatment for newly diagnosed glioblastoma multiforme (GBM) includes surgical resection, followed by adjuvant radiation and concurrent temozolomide (TMZ) chemotherapy. Almost invariably, GBM acquires resistance to TMZ, resulting in tumor recurrence and clinical deterioration. The advent of immunotherapy may be a promising development in the treatment of GBM. One potential immunotherapeutic approach involves activation of antigen-presenting cells to mount a stronger antitumor response by effector CD4+ and CD8+ T-cells. Dendritic cells, the main antigen-presenting cells in humans, have been utilized as immunotherapeutic agents in GBM.1 For instance, Kikuchi et al2 showed that autologous injection of fusion cells (FC), created by fusing the patient's glioma cells with his or her own dendritic cells, results in a potent antigen-presenting cells capable of powerful cytotoxic T-lymphocyte responses....Based on the successful results of immunotherapy against GBM with FC, Akasaki et al...